Extension Study MT-1186-A04 Evaluating Oral Edaravone (Radicava ORS®) Continued Efficacy and Safety up to an Additional 48 Weeks in Patients With ALS (P9-2.007)
Continue to examine the efficacy and safety of investigational once daily and FDA-approved on/off Radicava ORS® (edaravone) oral suspension (Mitsubishi Tanabe Pharma America [MTPA], hereafter “MTPA oral edaravone”) dosing regimens in patients with amyotrophic lateral sclerosis (ALS) for up to an additional 48 weeks in extension Study MT-1186-A04.
Authors
- Art Wamil
- Stephen Apple (ORCID: https://orcid.org/0000-0003-0982-9133)
- Amélia M. Silva (ORCID: https://orcid.org/0000-0002-7524-9914)
- Angela Genge (ORCID: https://orcid.org/0000-0001-5587-9946)
- Manabu Doyu (ORCID: https://orcid.org/0000-0002-6264-9927)
- Noah J. Sasson (ORCID: https://orcid.org/0000-0002-3676-1253)
- Jeffrey D. Rothstein (ORCID: https://orcid.org/0000-0003-2001-8470)
- Gen Sobue (ORCID: https://orcid.org/0000-0003-4769-5922)
- Lorne Zinman (ORCID: https://orcid.org/0000-0002-8096-8366)
- Fumihiro Takahashi (ORCID: https://orcid.org/0000-0001-5701-5332)
- Daniel Selness
- Marvin Chum (ORCID: https://orcid.org/0000-0002-2252-0846)
- Adriano Chiò (ORCID: https://orcid.org/0000-0001-9579-5341)
- Vesna Todorović
- Michelle Cecic
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Johns Hopkins University (US)
- Aichi Medical University (JP)
- Johns Hopkins Medicine (US)
- McMaster University Medical Centre (CA)
- Health Sciences Centre (CA)
- Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (IT)
- University of Turin (IT)
- Nagoya University (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210396
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00